Navigation Links
New Elekta Radiation Therapy Technology Takes Weeks Off of Lung Cancer Treatments
Date:9/19/2013

ATLANTA, Sept. 19, 2013 /PRNewswire/ – On September 4, Kettering Medical Center (Kettering, Ohio) became the first clinic in North America to use Elekta's Versa HD™ system to treat a patient, a 71-year-old woman with medically inoperable lung cancer.

The rapid speed of radiosurgery with Versa HD enabled Kettering physicians to reduce the number of treatment sessions for this patient from seven weeks to three days. In addition, each treatment session decreased from 40 minutes to less than 10 minutes.

"With Versa HD, we can cut total treatment times for our patients by at least three-to four-fold," says Douglas Einstein, MD, PhD, Chairman of Radiation Oncology at Kettering Medical Center. "This new technology has the potential to allow us to add more patients to the daily radiotherapy schedule, including patients with long commutes because the number of sessions could radically decrease. Just as important, the decreased treatment time per session will improve the patient experience.

"For example, lung cancer patients who receive radiosurgery may have their arms raised for a 40-minute session and that can be difficult for some patients," he adds. "The High Dose Rate mode of Versa HD allows us to shorten radiation beam delivery time and improve patient comfort in radiosurgery cases."

In 2012, an estimated 226,160 new cases of lung cancer were expected to be diagnosed in the US, representing almost 14 percent of all cancer diagnoses.[1]

"We can deliver advanced, state-of-the-art treatment with Versa HD and do it in a way that it not only effectively treats a patient's cancer, but also substantially decreases the impact of treatment on their quality of life," Dr. Einstein says.

To learn
'/>"/>

SOURCE Elekta
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Switzerlands Hopital Riviera Improves Confidence in Patient Treatment with Elektas Identify Solution
2. Elekta to Spotlight Versa HD System at 2013 ASTRO Annual Meeting
3. Elekta Introduces Groundbreaking Image Guidance Capabilities Integrated with Versa HD Cancer Treatment System
4. Johns Hopkins Kimmel Cancer Center Acquires Elekta Versa HD System
5. Elektas Leksell Gamma Knife Perfexion and Elekta Infinity Place First and Second in 2013 KLAS Radiation Therapy Report
6. Elekta to Exhibit New Versa HD Radiotherapy System at Annual Radiation Physics Conference
7. Odense Universitetshospital tilfører kræftpatienters stereotaktiske strålebehandling næsten tre gange hurtigere med Elektas Versa HD-system
8. Elekta Receives CE Marking for Clarity 4D Monitoring
9. Froedtert & The Medical College of Wisconsin Clinical Cancer Center Joins Elekta and Philips Research Consortium on MRI-Guided Radiation Therapy
10. Elektas Leksell Gamma Knife Perfexion Earns Top Rank in 2013s Best in KLAS for Radiation Therapy
11. Elekta-Equra Health Partnership to Increase South African Cancer Patients Access to Radiation Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014 Inovio ... successful results from its randomized, double-blind, placebo-controlled ... with biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) ... or 18. Treatment with VGX-3100, Inovio,s HPV16/18-specific ... to CIN1 or no disease, meeting the ...
(Date:7/23/2014)... , July 23, 2014  The management ... CBRX ) will hold a conference call on ... the second quarter ended June 30, 2014.  The ... 31, 2014Time: , 8:30 am EDTDial-in numbers: , ... or,International: (412) 317-0790Webcast (live & archive): , ...
(Date:7/23/2014)... Global healthcare company GSK reports Q2 results ... price competition and supply disruptions to its Consumer business. ... out that the company is very much in transition, citing ... about long-term prospects as well as the investments being ... Simon Dingemans adds that the company is reining ...
Breaking Medicine Technology:Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 3Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 4Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 5Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2
(Date:7/23/2014)... The routine use of a molecular ... likelihood of performing the correct initial surgery for ... from the University of Pittsburgh Cancer Institute (UPCI), ... at the UPMC/UPCI Multidisciplinary Thyroid Center and other ... getting the correct initial surgery by 30 percent, ...
(Date:7/23/2014)... FL (PRWEB) July 23, 2014 Men ... pay higher premiums for life insurance based on national ... cheap life insurance rates search to its comprehensive tool ... at http://quotespros.com/life-insurance.html . , Providers that are ... selected, sorted and reviewed in one or two clicks. ...
(Date:7/23/2014)... near Sellafield or Dounreay since the 1990s are not ... research published in the British Journal of Cancer ... Research Group at the University of Oxford and from ... among those who were under 25 and living near ... in cancer incidence from 1991-2006 between those living near ...
(Date:7/23/2014)... New York, New York (PRWEB) July 23, 2014 ... that the use of a power morcellator ( http://www.injurybeacon.com/power-morcellator/ ... uterine sarcoma and other cancers throughout a woman’s body, ... on July 22nd in the Journal of the American ... hysterectomy using a power morcellator at 500 U.S. hospitals ...
(Date:7/23/2014)... Asking patients if a suspicious skin lesion is ... spot is likely to be cancerous, according to a ... the Department of Dermatology at Temple University School of ... Dermatology on July 23, 2014, found that nearly ... by itching, while 28.2 percent involve pain. Non-melanoma skin ...
Breaking Medicine News(10 mins):Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 2Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 3Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 4Health News:Cheap Life Insurance Rates for Married Couples Added to Search System at Insurer Portal Online 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2
... ... with blogs, groups, forums, photos and videos , ... Norfolk, Va. (PRWEB) November 2, 2009 -- HealthCareerWeb.com, a full service healthcare ... online health care jobs section with its medical professional network . , ...
... 2 STANDUP FOR KIDS has been chosen by STAR ... businesses are being asked to join forces for charity ... for November,s National Homeless Youth Awareness Month. Local business ... OF THE NEIGHBORHOOD, are displaying posters and encouraging their customers ...
... On Thursday, November 5, 2009, at 8:30 a.m. Eastern/2:30 p.m. ... (Nasdaq and MTA: CTIC) management team will host a conference ... , , Conference Call Numbers, ... p.m. Central European/5:30 a.m. Pacific Time, 1-877-941-6010 ...
... , the journal of the American Academy of Ophthalmology ... surgery is likely to benefit patients with age-related macular ... a clinical trial showing that the steroid triamcinolone may ... when standard treatment fails, and on the public,s use ...
... Nov. 1 Schering-Plough Corporation (NYSE: SGP ) ... with boceprevir combination therapy in patients with chronic hepatitis ... were presented at the American Association for the Study ... 30-Nov. 3. , Boceprevir is an investigational ...
... body fat means greater survival odds, researcher says , SUNDAY, Nov. ... are much more likely to die than other people on dialysis, ... study has found. , Researchers measured body fat percentage in 671 ... rate for people with less than 10 percent body fat was ...
Cached Medicine News:Health News:HealthCareerWeb.com is Redesigned to Integrate Healthcare Job Board with Medical Professional Network 2Health News:HealthCareerWeb.com is Redesigned to Integrate Healthcare Job Board with Medical Professional Network 3Health News:Local Businesses Unite, Calling an End to Youth Homelessness 2Health News:Cataract surgery helps AMD patients; steroid improves DME; online eye health forum 2Health News:Cataract surgery helps AMD patients; steroid improves DME; online eye health forum 3Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 2Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 3Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 4Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 5Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 6Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 7Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 8Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 9Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 10Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 11
The reliable and easy-to-use 3900/P pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
... Digital Pulse Oximeter monitors SpO2, ... It is designed to provide ... patients. The device rejects spontaneous ... the operator of excess artifacts ...
... The 8600FO is designed to ... MRI users for patient safety ... Fiber Optic Sensors and Cables ... is eliminated, as well as ...
... The 8600 Series Tabletop/Portable ... simple universal tool for patient ... continuous monitoring, the 8600 has ... professionals worldwide and is recognized ...
Medicine Products: